{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:45:10Z","timestamp":1789706710323,"version":"4.0.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Qual Life Res"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s11136-011-0012-7","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T18:00:54Z","timestamp":1317405654000},"page":"975-981","source":"Crossref","is-referenced-by-count":19,"title":["Determining the clinically important difference in visual analog scale scores in abuse liability studies evaluating novel opioid formulations"],"prefix":"10.1007","volume":"21","author":[{"given":"Thomas A.","family":"Eaton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra D.","family":"Comer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis A.","family":"Revicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah J.","family":"Trudeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"van Inwegen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel P.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,10,1]]},"reference":[{"key":"12_CR1","unstructured":"Kweder, S. L. (2006). Congressional testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Food and Drug Administration."},{"key":"12_CR2","unstructured":"Department of Health and Human Services. (2009). Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: draft guidance. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf . Accessed 25 Aug 2011."},{"key":"12_CR3","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1097\/00005650-200110000-00002","volume":"39","author":"GR Norman","year":"2001","unstructured":"Norman, G. R., Sridhar, F. G., Guyatt, G. H., & Walter, S. D. (2001). Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life. Medical Care, 39, 1039\u20131047.","journal-title":"Medical Care"},{"key":"12_CR4","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4065\/77.4.371","volume":"77","author":"GH Guyatt","year":"2002","unstructured":"Guyatt, G. H., Osoba, D., Wu, A. W., Wyrwich, K. W., & Norman, G. R. (2002). Methods to explain the clinical significance of health status measures. Mayo Clinic Proceedings, 77, 371\u2013383.","journal-title":"Mayo Clinic Proceedings"},{"key":"12_CR5","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11136-004-0705-2","volume":"14","author":"KW Wyrwich","year":"2005","unstructured":"Wyrwich, K. W., Bullinger, M., Aaronson, N., et al. (2005). Estimating clinically significant differences in quality of life outcomes. Quality of Life Research, 14, 285\u2013295.","journal-title":"Quality of Life Research"},{"key":"12_CR6","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","volume":"61","author":"D Revicki","year":"2008","unstructured":"Revicki, D., Hays, R. D., Cella, D., & Sloan, J. (2008). Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology, 61, 102\u2013109.","journal-title":"Journal of Clinical Epidemiology"},{"key":"12_CR7","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","volume":"88","author":"JT Farrar","year":"2000","unstructured":"Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000). Defining the clinically important difference in pain outcome measures. Pain, 88, 287\u2013294.","journal-title":"Pain"},{"key":"12_CR8","unstructured":"Jones, J. B., Sokolowska, M., Setnik, B., Romach, M., Johnson, F., & Stauffer, J, et al. (2008). ALO-01, an investigational extended-release opioid formulation containing morphine sulfate and sequestered naltrexone: pharmacodynamic (drug liking) effects. Presented at 24th Annual meeting of the American Academy of Pain Medicine, Orlando, FL."},{"key":"12_CR9","unstructured":"Webster, L., Jones, J. B., Johnson, F., Sekora, D., & Stauffer, J. (2008). Relative drug-liking\/euphoria effects of intravenous morphine alone and in combination with naltrexone in recreational opioid users. Presented at 12th World Congress on Pain, Glasgow, Scotland."},{"key":"12_CR10","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s002130100909","volume":"159","author":"SD Comer","year":"2002","unstructured":"Comer, S. D., Collins, E. D., Kleber, H. D., et al. (2002). Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology, 159, 351\u2013360.","journal-title":"Psychopharmacology"},{"key":"12_CR11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer, S. D., Sullivan, M. A., Yu, E., et al. (2006). Injectable, sustained-release naltrexone for the treatment of opioid dependence: A randomized, placebo-controlled trial. Archives of General Psychiatry, 63, 210\u2013218.","journal-title":"Archives of General Psychiatry"},{"key":"12_CR12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00213-006-0509-x","volume":"189","author":"MA Sullivan","year":"2006","unstructured":"Sullivan, M. A., Vosburg, S. K., & Comer, S. D. (2006). Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology, 189, 37\u201346.","journal-title":"Psychopharmacology"},{"key":"12_CR13","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1080\/08039480701415251","volume":"61","author":"BA Johansson","year":"2007","unstructured":"Johansson, B. A., Berglund, M., & Lindgren, A. (2007). Efficacy of maintenance treatment with methadone for opioid dependence: A meta-analytical study. Nordic Journal of Psychiatry, 61, 288\u2013295.","journal-title":"Nordic Journal of Psychiatry"},{"key":"12_CR14","first-page":"582","volume":"41","author":"GR Norman","year":"2003","unstructured":"Norman, G. R., Sloan, J. A., & Wyrwich, K. W. (2003). Interpretation of changes in health-related quality of life: The remarkable universality of half a standard deviation. Medical Care, 41, 582\u2013592.","journal-title":"Medical Care"},{"key":"12_CR15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1023\/A:1014485627744","volume":"11","author":"KW Wyrwich","year":"2002","unstructured":"Wyrwich, K. W., Tierney, W. M., & Wolinsky, F. D. (2002). Using the standard error of measurement to identify important changes on the asthma quality of life questionnaire. Quality of Life Research, 11, 1\u20137.","journal-title":"Quality of Life Research"},{"issue":"Suppl 1","key":"12_CR16","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1016\/j.drugalcdep.2006.01.015","volume":"83","author":"S McColl","year":"2006","unstructured":"McColl, S., & Sellers, E. M. (2006). Research design strategies to evaluate the impact of formulations on abuse liability. Drug and Alcohol Dependence, 83(Suppl 1), S52\u2013S62.","journal-title":"Drug and Alcohol Dependence"},{"key":"12_CR17","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/11530800-000000000-00000","volume":"29","author":"J Stauffer","year":"2009","unstructured":"Stauffer, J., Setnik, B., Sokolowska, M., Romach, M., Johnson, F., & Sellers, E. (2009). Subjective effects and safety of whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users: A randomized, double-blind, placebo-controlled, crossover study. Clinical Drug Investigation, 29, 777\u2013790.","journal-title":"Clinical Drug Investigation"}],"container-title":["Quality of Life Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-011-0012-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11136-011-0012-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11136-011-0012-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T08:00:18Z","timestamp":1559376018000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11136-011-0012-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,1]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["12"],"URL":"https:\/\/doi.org\/10.1007\/s11136-011-0012-7","relation":{},"ISSN":["0962-9343","1573-2649"],"issn-type":[{"value":"0962-9343","type":"print"},{"value":"1573-2649","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,1]]}}}